key: cord-0747292-o9mk1gmm
authors: Remes‐Troche, José María; Velarde‐Ruiz Velasco, José Antonio
title: The Liver and COVID‐19 in Mexico
date: 2021-08-27
journal: Clin Liver Dis (Hoboken)
DOI: 10.1002/cld.1153
sha: 4b4c21bd439b14f2fabd5c785091cc1376b6e86b
doc_id: 747292
cord_uid: o9mk1gmm

nan

The Mexican government declared a national health emergency on March 30 and implemented restrictions in the public, private, and social sectors which include: voluntary quarantine (lock-down), school closings, social distancing, and limitation of non-essential activities. Simultaneously, the number of cases (especially severe cases) increased, and as in other parts of the world, it was reported that between up to 30% of Mexican patients infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) developed gastrointestinal and liver manifestations ( Fig. 1) . 4, 5 Immediately, medical associations dedicated to gastroenterology and hepatology in Mexico issued recommendations and guidelines for the identification, management, and treatment of patients with liver manifestations associated with SARS-CoV-2, as well as for patients with pre-existing liver disease and liver transplant. 7, 8 Also, the groups dedicated to the research of liver diseases in Mexico in collaboration with national and international partners undertook the task of describing the first series of cases, risk factors, and mortality associated with COVID-19 in Mexicans (Table 1) .

liver DaMaGe DUe TO sars-COv-2 Liver injury in COVID-19 patients is related to several factors, including direct cytopathic effect of the virus, immune-mediated collateral damage, or an exacerbation of preexisting liver disease. 6 As in other cases series, abnormal liver functions tests (LFT) was a common finding in Mexican patients with COVID-19. In the first cohort reported in our country in May 2020, abnormal liver enzyme levels were review abnormal in 33% of cases and this finding was associated with mortality. 4 In a prospective study coordinated by the Latin American Association for the Study of the Liver (ALEH) in 1,611 hospitalized patients, abnormal LFT on admission were present on 45.2% of the cohort and mortality was 15.1%. 9 Patients with abnormal LFT on admission presented higher mortality 18.7% compared to those with normal liver biochemistries 12.2% (P < 0.0001). After excluding patients with history of chronic liver disease, abnormal LFT on admission were independently associated with death and severe COVID-19, both adjusted by age, gender, diabetes, pneumonia, and body mass index >30. Similar results have shown in recent prospective multicenter international cohort among 829 hospitalized patients (203 from Mexico), in whom hypertransaminasemia was present in 267 patients (32.3%) and liver injury during hospitalization was associated with a higher hospital stay (>10 days) and worst outcome. 5 Further studies in our population have shown consistently that abnormal LFT, in particular alanine aminotransferase and aspartate aminotransferase, were associated with a higher in-hospital mortality risk (Table 1) . 10, 11 PreeXisTinG liver Disease anD COviD-19

Although initial data reported that previous liver disease was not associated with severity, later studies shown an important association between preexisting liver disease (such as nonalcoholic fatty liver disease [NAFLD]) and COVID-19. As expected, due to high prevalence of overweight and obesity in our population, studies in Mexican COVID-19 patients have found a high prevalence of metabolic comorbidities, which included hypertension, NAFLD and type 2 diabetes. In a retrospective study in 155 hospitalized Mexican patients, abnormal LFT were present in 96.8%, prevalence of steatosis was 42.6% and of significative liver fibrosis was 44.5%. 12 Liver fibrosis by FIB-4 was associated with risk of intensive care unit (ICU) admission (odds ratio [OR] 1.74; P = 0.023) and mortality (OR 6.45, P = 0.002); but no independent associations were found. In a more recent study Campos-Murgía et al. 13 found in 432 hospitalized patients with COVID-19 that 40.6% fulfilled criteria for metabolic associated fatty liver disease (MAFLD). Although the authors did not find significant differences in the outcomes of hospitalized patients with MAFLD and those without MAFLD, a significant increase in the risk of mechanical ventilation requirement, acute kidney injury, and mortality in patients with MAFLD and advanced liver was found. The role of MAFLD in the outcomes of patients with COVID-19 is still controversial.

Drug-induced liver injury (DILI) should be considered among the important differentials of liver injury in 

In summary, despite the high prevalence of metabolic diseases and chronic alcohol consumption in Mexico, the impact of the SARS-CoV-2 on the liver in Mexican patients was similar to that described in other parts of the world. The long-term effects and sequelae of liver function in Mexican patients with pre-existing liver disease are yet to be determined.

Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal

COVID-19 in Latin America: The Implications of the First Confirmed Case in Brazil

Initial gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2 infection in 112 patients from veracruz in Southeastern Mexico

TIVURON project: an international multicenter prospective cohort study evaluating the gastrointestinal symptoms and complications of covid-19 in hospitalized patients

Direct or collateral liver damage in SARS-CoV-2-infected patients

Hepatic manifestations and impact of COVID-19 on the cirrhotic patient

Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic

Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission

Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study

Impact of liver enzymes on SARS-CoV-2 infection and the severity of clinical course of COVID-19

Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19